Merck: license agreement in Nash disease

(CercleFinance.com) - Merck announced on Tuesday that it has signed a license agreement with Hanmi Pharmaceutical of South Korea to develop and commercialize its investigational treatment for NASH liver disease.


Under the terms of the agreement, Merck will obtain an exclusive license to develop, manufacture and distribute Hanmi's efinopegdutide in the US and worldwide.

In return, Hanmi will receive an immediate payment of 10 million dollars and may be entitled to receive up to 860 million dollars in milestone payments, based on the product's progress, which has recently undergone phase II clinical trials.


Copyright (c) 2020 CercleFinance.com. All rights reserved.